Brief: U.S. FDA Approves Welireg Plus Lenvima For Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
25/09/2026 11:47
BRIEF-U.S. FDA Approves Welireg Plus Lenvima For Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component Sept 25 (Reuters) - Merck & Co Inc MRK.N:
U.S. FDA APPROVES WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) FOR CERTAIN PREVIOUSLY TREATED ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT (CCRCC)
Source text: ID:nBw5cV9kca
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines